was rising in the premarket after getting an expanded contract from the Army to produce reagents to detect biochemical weapons.

The Sunnyvale, Calif., company said the pact from the Army Medical Research Institute for Infectious Disease was expanded by $3.4 million over the next two years.

Cepheid's shares were rising 4% to $3.44 on Instinet.